SEARCH

SEARCH BY CITATION

References

  • 1
    Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirke O, de Wit S, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 21172125.
  • 2
    Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755
  • 3
    Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18: 20392045.
  • 4
    Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.
  • 5
    Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 4957.
  • 6
    Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, Sáez C, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767774.
  • 7
    Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11: 839846.
  • 8
    Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42: 262270.
  • 9
    Martín-Carbonero L, Benhamou Y, Puoti M, Belenguer J, Mallotas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128133.
  • 10
    Soriano V, Maida I, Nunez M, Garcia-Samaniego J, Barreiro P, Martín-Carbonero L, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9: 987992.
  • 11
    Pineda JA, Romero-Gómez M, Díaz-García F, Girón-González JA, Montero JL, Torre-Cisneros JL, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. HEPATOLOGY 2005; 41: 779789.
  • 12
    Garcia-Samaniego J, Soriano V, Miro JM, Romero JD, Bruguera M, Castilla J, et al. Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000. HIV Clin Trials 2002; 3: 99114
  • 13
    Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del Romero J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11: 217.
  • 14
    Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. J Hepatol 2005; 42: 615624.
  • 15
    de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846852.
  • 16
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421430.
  • 17
    Ginés P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 18191827.
  • 18
    Benhamou Y, Di Martino V, Bochet M, Colombet C, Thibault V, Liou M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. HEPATOLOGY 2001; 34: 283287.
  • 19
    Mariné-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18: 21632170.
  • 20
    McGovern B, Golan Y, Lopez M, Pratt D, Lawton A, Moore G, et al. The impact of cirrhosis on CD4 T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431437.
  • 21
    Massard J, Ratziu V, Thabut D, Mousalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44( Suppl 1): S19S24.
  • 22
    Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol 2004; 40: 823830.
  • 23
    Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890895.
  • 24
    Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636644.
    Direct Link:
  • 25
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105114.
  • 26
    Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 43: 911912.
  • 27
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 28
    Sangiovanni A, Prati GM, Fasani F, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. HEPATOLOGY 2006; 43: 13031310.
  • 29
    Bruno R, Sacchi P, Patrono S, Maiocchi L, Filice G. Hierarchy of liver related major complications in a cohort of coinfected patients with compensated liver cirrhosis. In: Abstract of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February 2006: Poster no. 873.
  • 30
    Miró JM, Murillas, J, Laguno M, de Lazzari E, Moitinho E, Moreno A, et al. Natural history and prognosis of end-stage liver disease in Spanish HIV-1 infected patients: a prospective cohort study of 104 patients (1999–2004). In: Abstract of the 10th European AIDS Conference, Dublin, Ireland, November 2005: Abstract no. PS7/1.
  • 31
    García-García JA, Romero-Gómez M, Girón-González JA, Rivera-Irigoin R, Torre-Cisneros J, Montero JL, et al. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus-coinfected patients with decompensated cirrhosis. AIDS Res Hum Retrovir 2006; 22: 12361241.